Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-05
2011-07-05
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07973137
ABSTRACT:
Compositions comprising a cell in which a molecular complex with high affinity for its cognate ligand is bound to the surface of the cell are provided. To form the molecular complexes, extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. Optionally, identical antigenic peptides can be bound to each ligand binding site of a molecular complex.
REFERENCES:
patent: 5583031 (1996-12-01), Stern
patent: 6015884 (2000-01-01), Schneck et al.
patent: 6140113 (2000-10-01), Schneck et al.
patent: 6268411 (2001-07-01), Schneck et al.
patent: 6269411 (2001-07-01), Reasoner
patent: 6448071 (2002-09-01), Schneck et al.
patent: 6458354 (2002-10-01), Schneck et al.
patent: 6787154 (2004-09-01), Albani
patent: 2002/0006903 (2002-01-01), Schneck et al.
patent: 2002/0119121 (2002-08-01), Vitiello et al.
patent: 2002/0122818 (2002-09-01), Albani
patent: 2003/0077248 (2003-04-01), Moriarty et al.
patent: 93/10220 (1993-05-01), None
patent: WO 93/10220 (1993-05-01), None
patent: WO 94/09131 (1994-04-01), None
patent: 96/04314 (1996-02-01), None
patent: WO 00/40968 (2000-07-01), None
patent: WO 01/80833 (2001-11-01), None
patent: WO 01/94944 (2001-12-01), None
patent: WO 02/065992 (2002-08-01), None
patent: WO 03/057171 (2003-07-01), None
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Zwirner J et al (J. Immunol. Jan. 1992;148(1):272-276).
Kuwana et al (Biochem Biophys Res Commun Dec. 1987;149(3):960-968).
Seimiya H et al (J Biochem (Tokyo) Jun. 1993;113(6):687-91).
Matsui et al (Proc. Natl. Acad. Sci., USA, 91(26)12862-12866, Dec. 20, 1994).
J. Dal Porto et al. “A soluble divalent class I major historcompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations” Proceedings of the National Academy of Science of the USA vol. 90, No. 14, Jul. 15, 1993 pp. 6671-6675.
T. Johansen et al. “Potent inhibition of alloreactive T cells by nanomolar concentrations of a divalent soluble class I MHC molecule” The Journal of Immunology, vol. 150, No. 8, part 2, Apr. 15, 1993, p. 83A.
C. Gregoire et al. “Engineered secreted T-cell receptor alpha-beta heterodimers” Proceedings of the National Academy of Sciences of the USA vol. 88, No. 18, Sep. 15, 1991, pp. 8077-8081.
D. Eilat et al. “Secretion of a soluble, chimeric gamma-delta T-cell receptor-immunoglobulin heterodimer” Proceedings of the National Academy of Sciences of the USA, vol. 89, No. 15, Aug. 1, 1992, pp. 6871-6875.
S. Weber et al. “Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor” Nature, vol. 356, No. 6372, Apr. 30, 1992, pp. 792-976.
H-C Chang et al. “A general method for facilitating heterodimeric pairing between two proteins: Application to expression of alpha and beta T-cell receptor extracellular segments” Proceedings of the National Academy of Sciences of the USA, vol. 91, Nov. 1994, pp. 11408-11412.
S. O'Herrin et al. “Expression and analysis of soluble MHC- and TcR-immunoglobulin super dimers” The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996 p. A1473.
J. Schneck et al. “Specific inhibition of graft rejection by soluble MHC superdimers” The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996, p. A1473.
M. Lebowitz et al. “Specificity of soluble 2C TcR/Ig superdimers for peptide/MHC complexes” The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996, p. A1178.
U.S. Appl. No. 09/642,660, Schneck et al.
Goldberg et al., “In vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen),”J. Immunol. 170, 228-35, 2003.
Latouche & Sadelain, “Induction of human cytotoxic T lymphocytes by artifical antigen-presenting cells,”Nature Biotechnol. 18, 405-09, Apr. 2000.
Levine et al., “Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T cells in the Absence of Exogenous Feeder Cells,”J. Immunol. 159, 5921-30, 1997.
Maus et al., “Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB,”Nature Biotechnol. 20, 143-48, Feb. 2002.
Maus et al., “HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells,”Clin. Immunol. 106, 16-22, 2003.
Nakamura et al., “Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity”,Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 8, No. 8, Aug. 2002, pp. 2742-2749.
Oelke et al., “Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells”,Nature Medicine, vol. 9, No. 5, May 2003, pp. 619-624.
Oelke et al., “Generation and purification of CD8+melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy”,Clinical Cancer Research; An Official Journal of the American Association for Cancer Research, May 2000, vol. 6, No. 5, pp. 1997-2005.
Von Bergwelt-Baildon et al., “Human primary and memory cytotoxic T lymphocyte responses are effectively induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application”,Blood, vol. 99, No. 9, May 1, 2002, pp. 3319-3325.
Deeths et al., “B7-1-Dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+and CD8+T cells”, European Journal of Immunology, vol. 27, No. 3, 1997, pp. 598-608.
Oertli et al., “Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+lymphocytes invitro”, Clinical and Experimental Immunology, vol. 110, No. 1, Oct. 1997, pp. 144-149.
Hamad Abdel
Lebowitz Michael S.
O'Herrin Sean
Schneck Jonathan
Aeder Sean E
Banner & Witcoff , Ltd.
Johns Hopkins University
LandOfFree
Cell compositions comprising molecular complexes that modify... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell compositions comprising molecular complexes that modify..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell compositions comprising molecular complexes that modify... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689485